Clinical and economic assessment of using IRS®19 for the treatment and prevention of acute respiratory infections in children

Objective: to perform pharmacoeconomic analysis of the feasibility of using topical bacterial lysate in the form of nasal spray (IRS®19) for the treatment and prevention of upper respiratory tract infections in pediatric population in comparison with other drugs registered in Russia, belonging to the class of topical interferons.

Material and methods. Based on the Rosstat data and information from open sources, the population of patients with acute respiratory infections (ARI) was calculated. Considering the Russian clinical recommendations “Acute respiratory viral infection (ARVI)” and “Acute tonsillitis and pharyngitis (acute tonsillopharyngitis)”, the direct medical costs of providing medical care to specialized patients were determined. Direct costs on the part of parents included all costs for purchasing medicines for basic or concomitant therapy. Direct costs on the part of the healthcare system and the state included the costs of providing medical care at the outpatient stage. Direct non-medical costs included payments for disability leaves, indirect costs – lost gross domestic product (GDP) due to absence from work.

Results. The total costs of the healthcare system and the state for 1 AVI patient are 42,472 rubles in case of uncomplicated course and 70,649 rubles in case of complicated course. In case of IRS®19 application from the first day of the disease, it is possible to reduce its duration by more than two-fold. Thus, the costs of medical care amount to 2,078 rubles. Payments for disability leaves by the Social Fund of Russia will amount to 2,287 rubles, and the lost GDP – 9,148 rubles (total costs 13,513 rubles).

Conclusion. For the first time in Russian economic conditions, the use of IRS®19 for ARI treatment and prevention in children was evaluated. IRS®19 application from the first symptoms of the disease allows refusing the use of topical interferons, reduces the duration of symptoms and the need for prescription of antitussives, vasoconstrictors, and antibiotics.

1. Williams B.G., Gouws E., Boschi-Pinto C., et al. Estimates of worldwide distribution of child deaths from acute respiratory infections. Lancet Infect Dis. 2002; 2 (1): 25–32. https://doi.org/10.1016/s1473-3099(01)00170-0.

2. Choi E., Ha K.S., Song D.J., et al. Clinical and laboratory profiles of hospitalized children with acute respiratory virus infection. Korean J Pediatr. 2018; 61 (6): 180–6. https://doi.org/10.3345/kjp.2018.61.6.180.

3. Ramaekers K., Keyaerts E., Rector A., et al. Prevalence and seasonality of six respiratory viruses during five consecutive epidemic seasons in Belgium. J Clin Virol. 2017; 94: 72–8. https://doi.org/10.1016/j.jcv.2017.07.011.

4. Acute respiratory viral infection (ARVI). Clinical guidelines. 2022. Available at: https://cr.minzdrav.gov.ru/recomend/25_2 (in Russ.) (accessed 25.02.2024).

5. Thompson M., Vodicka T.A., Blair P.S., et al. Duration of symptoms of respiratory tract infections in children: systematic review. BMJ. 2013; 347: f7027. https://doi.org/10.1136/bmj.f7027.

6. Svistushkin V.M., Nikiforova G.N., Zolotova A.V., Stepanova V.A. Using of topical bacterial lysates in modern clinical practice. Meditsinskiy sovet / Medical Council. 2021; 6: 49–56 (in Russ.). https://doi.org/10.21518/2079-701X-2021-6-49-56.

7. Leonova M.V., Efremenkova O.V., Shmeleva N.I., Belousov Yu.B. The use IRS 19 in children for the treatment and prevention of upper respiratory tract infections. Detskie Infektsii / Children Infections. 2004; 3 (4): 45–8 (in Russ.).

8. Kladova O.V., Uchaykin V.F., Demina E.D., et al. Local immunomodulator IRS 19 in complex therapy of acute respiratory infections. Detskie Infektsii / Children Infections. 2006; 5 (4): 51–4 (in Russ.).

9. Kreminets' O.I., Kozak L.Ya., Maksymiv O.V., et al. Experience of application of preparation IRS 19 in treatment of sharp diseases of the top respiratory ways at children. Meditsina transporta Ukrainy / Medicine of Ukrainian Transport. 2005; 2: 59–62 (in Russ.).

10. Korovina N.A., Lepiseva I.V., Platnikova L.V., et al. The effectiveness of topical immunotherapy with bacterial lysates in frequently ill children. Pediatrics. Journal named after G.N. Speransky. 2009; 88 (5): 104–9 (in Russ.).

11. Federal State Statistics Service. Available at: https://rosstat.gov.ru/ (in Russ.) (accessed 10.02.2024).

12. Acute tonsillitis and pharyngitis (acute tonsillopharyngitis). Clinical guidelines. 2021. Available at: https://cr.minzdrav.gov.ru/recomend/306_2 (in Russ.) (accessed 10.02.2024).

13. The official website of the Territorial Fund of the Ministry of Health of Saint Petersburg. The Commission for the Development of the Territorial Program of Compulsory Health Insurance in Saint Petersburg. General Tariff Agreement for 2023. Available at: https://spboms.ru/page/docs (in Russ.) (accessed 10.02.2024).

14. Federal Law of 29.12.2006 No. 255-FZ “On Compulsory Social Insurance in case of temporary disability and in connection with maternity”. Available at: https://base.garant.ru/12151284/ (in Russ.) (accessed 25.02.2024).

15. Sologub T.V., Golobokov G.S., Tsvetkov V.V., Tokin I.I. Interferongamma in the treatment of influenza and other respiratory viral infections. Meditsinskiy sovet / Medical Council. 2015; 7: 54–8 (in Russ.).

16. Osidak L.V., Golovacheva E.G., Afanasyeva O.I., et al. Evaluation of the therapeutic efficacy of two recombinant interferon α-2b medications for intranasal administration (Genferon® light and Grippferon®) for ARVI in infants and young children. Pediatrics. Journal named after G.N. Speransky. 2017; 96 (2): 74–80 (in Russ.).

17. Trukhan D.I., Mazurov A.L., Rechapova L.A. Acute respiratory viral infections: current issues of diagnosis, prevention and treatment for therapists. Terapevticheskii arkhiv. 2016; 88 (11): 76–82 (in Russ.). https://doi.org/10.17116/terarkh2016881176-82.